Encompassing an industry-led agenda including academic keynote presentations, SMi's 9th annual conference on Imaging in Cancer Drug Development will be a unique opportunity to witness presentations on the current developments surrounding: oncology and diagnostic imaging modalities, drug development and clinical development alongside networking with key industry professionals.
This leading event will provide attendees with a complete view of the field and will focus primarily on oncology imaging modalities and applications in pre-clinical case studies, clinical imaging applications and innovations in imaging technology. This highly informative event will bring together key opinion leaders in the field to provide attendees with a comprehensive look into current advances in oncology imaging.
This year's agenda offers an unmatched opportunity for debate and resolution of key challenges currently facing the field. This will encourage attendees to discuss growth in the field and exchange ideas, therefore driving the field forward and ensuring sufficient treatment of the key issues surrounding oncology imaging and drug development.
- Evaluate the expansion of medical imaging products currently in the market
- Discover the latest innovations in software platforms and diagnostic solutions
- Build strategic partnerships with experts in the field
- Understand the cost containment programmes in key markets
- Explore standardisation and development of proficiency in the field
New for 2013:
• Balance of pre-clinical and clinical imaging modalities
• Spotlight on imaging biomarkers for efficient prognosis
• Considering multi-faceted datasets
This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in:
• Imaging and Translational Medicine
• Molecular Imaging
• Cancer Research
• Oncology
• Pre-clinical Imaging
• Clinical Imaging
• PET Research
• Biomarkers
• Target Discovery
• Pharmacokinetics/Pharmacodynamics
• Drug Discovery & Design
• Computer-Aided Drug Design
• Computational Chemistry
• Structure and Informatics
• Molecular Interaction
• Medical Imaging
• Clinical Pharmacology
• Biophysics
• Screening
• Clinical Development
• Structural Biology
Abbott Laboratories; ABX-CRO; AstraZeneca; Bayer Schering Pharma; BioClinica; Biomedical Systems; Biomedical Systems Europe; Biospace Lab; Bracco Imaging Spa; BTG; Cancer Research UK; Clinical and Experimental Pharmacology Paterson Institute for Cancer Research University of Manchester; Clinical Imaging Centre - Glaxo Smith Kline; CoreLabPartners; Cosmix Molecular Biologicals; Cronus Technologies; Daiichi Sankyo CO LTD; EORTC; F. Hoffmann-La Roche; GlaxoSmithKline; GSK; ICON Development Solutions; ICON Medical Imaging; Imagingequipment; Imanova; Imperial College London; InfoGoSoft; Institute of Cancer Research; iThera Medical; Kings College; LEO Pharma; MEDIAN Technologies; Medicines & Healthcare Products Regulatory Agency (MHRA) ; Merck; MHRA; Miltenyi Biotech Inc; nanoPET Pharma GmbH; Newcastle University; NHS Innovations London ; Novartis International AG; Oncology Pharma Ltd; Orion Pharma; Perceptive Informatics; Poznan University of Medical Sciences; Roche Diagnostics; Teva Pharmaceuticals Ltd; TNO Pharma; U T M D Anderson Cancer Center; UCL; UCL Cancer Institute; UCL Centre for Advanced Biomedical Imaging; Vision Healthcare Consultancy Ltd; VU University Medical Center;